APA

Kneitz B., Krebs M., Kalogirou C., Schubert M., Joniau S., van Poppel H., Lerut E., Kneitz S., Scholz C. J., Ströbel P., Gessler M., Riedmiller H. & Spahn M. (20140706). Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. : Cancer research.

Chicago

Kneitz Burkhard, Krebs Markus, Kalogirou Charis, Schubert Maria, Joniau Steven, van Poppel Hein, Lerut Evelyne, Kneitz Susanne, Scholz Claus Jürgen, Ströbel Philipp, Gessler Manfred, Riedmiller Hubertus and Spahn Martin. 20140706. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. : Cancer research.

Harvard

Kneitz B., Krebs M., Kalogirou C., Schubert M., Joniau S., van Poppel H., Lerut E., Kneitz S., Scholz C. J., Ströbel P., Gessler M., Riedmiller H. and Spahn M. (20140706). Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. : Cancer research.

MLA

Kneitz Burkhard, Krebs Markus, Kalogirou Charis, Schubert Maria, Joniau Steven, van Poppel Hein, Lerut Evelyne, Kneitz Susanne, Scholz Claus Jürgen, Ströbel Philipp, Gessler Manfred, Riedmiller Hubertus and Spahn Martin. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. : Cancer research. 20140706.